SUBSCRIBE
SUBSCRIBE
News   FDA

Bristol-Myers Squibb Company Obtains Japan Approval For Baraclude, Treatment For Chronic Hepatitis B Patients

August 4, 2006 | 
1 min read
Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry.
FDA Approvals Asia
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Tourist camp with fire, tent and firewood
Series A
New biotech cAMPfield emerges with $180M to reshape IBD treatment
June 18, 2026
 · 
2 min read
 · 
Gabrielle Masson
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Approvals
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI
June 18, 2026
 · 
2 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Huntington’s disease
UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again
June 17, 2026
 · 
4 min read
 · 
Heather McKenzie
Podcast
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
June 17, 2026
 · 
2 min read
 · 
Jef Akst